Dr. Dorato has over 45 years of experience in pharmacology, toxicology and drug development. He has spent 30 years at Eli Lilly and Co, retiring as Executive Director, Toxicology and Greenfield Laboratories Site Head. Dr. Dorato also has significant experience in the Toxicology CRO industry, spending 5 years at Covance as Vice President and CSO Global Discovery Services; 5 years at Smithers Avanza as Executive Vice President Toxicology Services; 2 Years at Inotiv, as Sr. Vice President Toxicology and Pharmacology. In these positions he has led global organizations in safety and efficacy, lead optimization, investigative and regulatory toxicology, discovery and late phase pathology, animal welfare, molecular and anatomical imaging, in vivo pharmacology (oncology, neuroscience, cardiovascular and metabolic disease, inflammation, renal, bone, receptor occupancy), developmental and reproductive toxicology, and model development. Dr. Dorato has led drug development decisions in various phases of pharmaceutical research and development, organizational growth initiatives, and development of leaders. He is a Fellow of the Academy of Toxicological Sciences, a Diplomate of the American Board of Toxicology, an Emeritus member of the Society of Toxicology and a full member of the American College of Toxicology.